. Author manuscript; available in PMC: 2013 Jan 6.

Published in final edited form as: Pharmacogenomics. 2012 Dec;13(16):1937–1950. doi: 10.2217/pgs.12.171

Table 2.

Allele and genotype frequency distributions of CYP2C9 and VKORC1 -1639G>A polymorphisms in 163 Puerto Rican patients treated with warfarin at the Veterans Affairs Caribbean Healthcare System (PR, USA).

Genotype/alleles	n; % (95% CI)	χ² test
VKORC1 -1639G>A

GG	68; 41.7 (40.9–42.5)	0.6
GA	75; 46 (45.2–46.8)
AA	20; 12.3 (11.8–12.8)
G	211; 64.7 (64.2–65.2)
A	115; 35.3 (34.8–35.8)

CYP2C9

1/1	120; 73.6 (72.9–74.3)	3.09
1/2	24; 14.7 (14.2–15.2)
1/3	8; 5 (4.6–5.2)
1/5	2; 1.2 (1.0–1.4)
2/2	2; 1.2 (1.0–1.4)
2/3	6; 3.7 (3.4–4.0)
2/5	1; 0.6 (0.56–0.64)
*1	274; 84 (83.6–84.4)
*2	35; 10.7 (10.4–11.0)
*3	14; 4.3 (4.1–4.5)
*5	3; 1 (0.87–0.93)

Data expressed as percentage (95% CI). χ² test result is also included. χ² < 3.84 meets the Hardy–Weinberg equilibrium. Only those SNPs detected in the analyzed samples from Puerto Ricans are reported in this table. SNPs assigned by the HILOMet PhyzioType^™ system [9–10] as noncalls were excluded.